Johann de Bono

Johann de Bono at the Royal Marsden and ICR is one of the most influential figures in prostate cancer drug development, having led trials that established enzalutamide and abiraterone as pillars of mCRPC treatment. He was a co-developer of the RECIST criteria adaptation for prostate cancer and has advanced PARP inhibitors including olaparib in mCRPC through landmark trials. His drug development expertise spans early-phase prostate cancer trials to registration studies. He has received numerous international awards for his transformative contributions to the field.